DE60127264D1 - Humane disintegrinproteine - Google Patents

Humane disintegrinproteine

Info

Publication number
DE60127264D1
DE60127264D1 DE60127264T DE60127264T DE60127264D1 DE 60127264 D1 DE60127264 D1 DE 60127264D1 DE 60127264 T DE60127264 T DE 60127264T DE 60127264 T DE60127264 T DE 60127264T DE 60127264 D1 DE60127264 D1 DE 60127264D1
Authority
DE
Germany
Prior art keywords
disintegrine
humane
proteins
disintegrin
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60127264T
Other languages
English (en)
Other versions
DE60127264T2 (de
Inventor
Roy A Black
Kurt Poindexter
Bruce A Mosley
Robert F Dubose
Steven R Wiley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DE60127264D1 publication Critical patent/DE60127264D1/de
Application granted granted Critical
Publication of DE60127264T2 publication Critical patent/DE60127264T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
DE60127264T 2000-07-28 2001-07-27 Humane disintergrinproteine Expired - Fee Related DE60127264T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22183800P 2000-07-28 2000-07-28
US221838P 2000-07-28
US28255001P 2001-04-09 2001-04-09
US282550P 2001-04-09
PCT/US2001/023709 WO2002010405A2 (en) 2000-07-28 2001-07-27 A human disintegrin protein

Publications (2)

Publication Number Publication Date
DE60127264D1 true DE60127264D1 (de) 2007-04-26
DE60127264T2 DE60127264T2 (de) 2007-12-20

Family

ID=26916195

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60127264T Expired - Fee Related DE60127264T2 (de) 2000-07-28 2001-07-27 Humane disintergrinproteine

Country Status (9)

Country Link
EP (1) EP1305434B1 (de)
JP (1) JP2004504845A (de)
AT (1) ATE356877T1 (de)
AU (2) AU8084301A (de)
CA (1) CA2415433A1 (de)
DE (1) DE60127264T2 (de)
ES (1) ES2283424T3 (de)
MX (1) MXPA03000843A (de)
WO (1) WO2002010405A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746112A4 (de) * 2018-01-31 2021-10-20 Verra Therapeutics Verfahren und zusammensetzungen zur hemmung der biologischen aktivitäten von adam 9

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6359000A (en) * 1999-07-23 2001-02-13 Telemetry Technologies, Inc. System and method for a virtual network operations center
US6728770B1 (en) * 1999-12-03 2004-04-27 Storage Technology Corporation Method and apparatus for workload balancing along multiple communication paths to a plurality of devices
EP1263766A1 (de) * 2000-03-03 2002-12-11 Human Genome Sciences, Inc. Adam polynukleotide, polypeptide und antikörper
AU6531101A (en) * 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same

Also Published As

Publication number Publication date
ES2283424T3 (es) 2007-11-01
AU8084301A (en) 2002-02-13
EP1305434B1 (de) 2007-03-14
WO2002010405A2 (en) 2002-02-07
EP1305434A2 (de) 2003-05-02
JP2004504845A (ja) 2004-02-19
ATE356877T1 (de) 2007-04-15
AU2001280843B2 (en) 2006-12-07
MXPA03000843A (es) 2004-04-05
WO2002010405A3 (en) 2003-01-23
CA2415433A1 (en) 2002-02-07
DE60127264T2 (de) 2007-12-20

Similar Documents

Publication Publication Date Title
DE60143880D1 (de) Nukleinsäuren, welche für tramsmembran serin proteasen kodieren, die kodierten proteine und darauf basierende methoden
DE60118544D1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
PT1109787E (pt) Arilpiperazinas e sua utilizacao como inibidores de metaloproteinases
DK0907631T3 (da) Uorganiske ionreceptoraktive forbindelser
ATE335485T1 (de) Quinolin-enthaltende alpha-ketoamid-basierte inhibitoren von cystein- und serin protease
PT1178958E (pt) N-cianometilamidas como inibidores de proteases
DE60143476D1 (de) Mutiertes ionenkanalprotein enthaltende viren
ES2194209T3 (es) Inhibidores de metaloproteasa de tiol sulfona.
EA199900162A1 (ru) Ингибиторы клеточной адгезии
DK1064027T3 (da) APO-2 Ligand-anti-her-2-antistofsynergier
NZ506783A (en) Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
DE69832268D1 (en) Peptidyl-2-amino-1hydroxyalkansulfonsäuren als cystein-protease-inhibitoren
DE60224275D1 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DE69738930D1 (de) Methoden zur modulation der melaninsynthese
ATE470441T1 (de) Modulator der menschlichen mastzellaktivierung
MXPA03003207A (es) Materiales y metodos para modular la actividad de union de ligando/enzimatica de proteinas alfa/¦ que contienen un sitio regulador alosterico.
DE60134230D1 (de) Substraten und nachweise zur wirksamkeit von beta-secretase
ATE253920T1 (de) Phosphor enthaltende hemmer von cystein- und serin-proteasen
ATE343369T1 (de) Neue verwendung von proteinhydrolysaten
HUP0104022A2 (hu) Béta-szekretáz típusú aktivitással rendelkező polipeptidek
DE60127264D1 (de) Humane disintegrinproteine
AR033476A1 (es) Leche tratada resistente a la coagulacion acida para incrementar la biodisponibilidad de calcio, metodo para obtenerla, productos en base a leche elaborados con dicha leche tratada y metodos de elaboracion
NO20006159L (no) Corin, en serinprotease
DK1506313T3 (da) Fremgangsmåder til screening af modulatorer af den mitokondrielle NAD-afhængige deacetylase SIRT3

Legal Events

Date Code Title Description
8328 Change in the person/name/address of the agent

Representative=s name: DF-MP, 80333 MUENCHEN

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee